echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > Alz Res Therapy: Genome-wide penetrance relationship analysis may predict the genetic risk of dementia

    Alz Res Therapy: Genome-wide penetrance relationship analysis may predict the genetic risk of dementia

    • Last Update: 2021-12-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Alzheimer's disease (AD) is a chronic neurodegenerative disease characterized by extracellular deposition of β-amyloid and intracellular accumulation of phosphorylated tau protein
    .
    AD is the most common cause of dementia in the elderly.


    The incidence of people over 65 years old is about 1.



    Early-onset AD is usually caused by mutations in APP, PSEN1 or PSEN2, while late-onset AD (LOAD) is the most common form of AD, showing more complex genetic mechanisms
    .


    The apolipoprotein ε4 allele (APOE4) is the only common high-risk genetic variant associated with LOAD.
    Previous large-scale genome-wide association studies ( GWAS s) have found dozens of low-impact loci, which indicates that LOAD A large part of the genetic component of the disease remains unexplained


    .


    GWAS

    Rare variants, structural variants and genetic interactions are possible reasons for the genetic loss of complex diseases
    .
    Previous studies have identified rare coding variants of SORL1 and ABCA7, which can affect APP processing


    .


    The single nucleotide polymorphisms (SNPs) found in genome-wide association studies can only explain part of the inheritance of Alzheimer's disease (AD)
    .
    Penetrance is considered to be one of the main reasons for the "lost heredity" of AD


    .


    In this way, Hui Wang and others of Huazhong Agricultural University used three popular methods to carry out genome-wide penetrance screening for the clinical diagnosis of AD (N = 10,389)
    .
    The subsequent analysis is to eliminate false associations caused by possible confounding factors


    .


    diagnosis

    Then, the co-expression of candidate gene interactions in the brains of AD patients was examined, and their association with the intermediate phenotype of AD was analyzed
    .

    In addition, a new method has been developed to compile the apparent risk factors into an apparent risk score (ERS) based on multi-factor dimensionality reduction
    .
    Two independent data sets were used to evaluate the feasibility of ERS in AD risk prediction


    .


    They found interactions between two candidate genes with PFDR<0.
    05 (RAMP3-SEMA3A and NSMCE1-DGKE/C17orf67) and five other genes with PFDR<0.


    1


    The co-expression of the discovered interactions supports the biological interactions that may exist behind the observed statistical significance
    .

    In addition, they found that ERSs can identify high-risk individuals with early-onset AD
    .

    The combined risk score of SNPs and SNP-SNP interaction showed a slight but stable AUC in predicting the clinical status of AD
    .


    The important significance of this research lies in the discovery: Through the epigenetic analysis of the whole genome, new genetic interactions that may be involved in AD can be determined; ERS can be used as an indicator of AD genetic risk
    .


    Through genome-wide epigenetic analysis, new genetic interactions that may be involved in AD can be determined; ERS can be used as an indicator of AD genetic risk
    .


    Original source:


    Genome-wide epistasis analysis for Alzheimer's disease and implications for genetic risk prediction.
    Alz Res Therapy.

    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.